Middle East & Africa Molecular Diagnostics Market Forecast to 2030 - Regional Analysis - by Disease Area, Technology, Product and Services, and End User

The Middle East & Africa molecular diagnostics market is expected to grow from US$ 825.09 million in 2022 to US$ 1,532.25 million by 2030. It is estimated to grow at a CAGR of 8.0% from 2022 to 2030.

Molecular Diagnostics in Personalized Medicine Fuels Middle East & Africa Molecular Diagnostics Market

With progress in high-throughput techniques, genome research has become more convenient and cost effective. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to the conventional tests, which also involved culturing microbes in laboratory conditions in some cases. Using precision medicine, medical treatments and interventions are tailored to each patient based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. A wide range of molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity; making progression plans; examining molecular characteristics; and monitoring patient outcomes. In addition, molecular imaging can aid in the detection of tiny tumors and assessment of their activities, contributing significantly to the development and expansion of personalized medicine, research, clinical trials, and medical practice in oncology. A high-throughput genotyping platform can be used to detect genetic aberrations in clinical samples, and next-generation sequencing can be used to identify all types of cancer-causing changes. The introduction of these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases. With these approaches, cancer patients will be able to receive personalized medicine. Thus, with technology ever evolving, the market for molecular diagnostics seems to have a bright future.

Middle East & Africa Molecular Diagnostics Market Overview

The UAE, Saudi Arabia, and South Africa are major countries in the Middle East & Africa. Saudi Arabia held the largest share of the regional molecular diagnostics market in 2022. The market in the Middle East & Africa is anticipated to grow during 2022-2030 due to the rising prevalence of various chronic diseases such as cardiovascular diseases, diabetes, gastrointestinal diseases, and respiratory diseases and increasing government initiatives in terms of funding and healthcare-related policies.

Middle East & Africa Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Molecular Diagnostics Market Segmentation

The Middle East & Africa molecular diagnostics market is segmented into disease area, technology, product and services, end user, and country.

Based on disease area, the Middle East & Africa molecular diagnostics market is segmented into infectious disease, oncology, genetic testing, cardiac diseases, immune system disorders, and others. The infectious disease segment registered the largest Middle East & Africa molecular diagnostics market share in 2022.

Based on technology, the Middle East & Africa molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarrays, and others. The polymerase chain reaction (PCR) segment registered the largest Middle East & Africa molecular diagnostics market share in 2022. The polymerase chain reaction (PCR) is further sub segmented into RT-PCR, qPCR, multiplex PCR, and others.

Based on product and services, the Middle East & Africa molecular diagnostics market is segmented into assays and kits, instruments, and services and software. The assays and kits segment registered the largest Middle East & Africa molecular diagnostics market share in 2022.

Based on end users, the Middle East & Africa molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics, research and academic institutes, and others. The diagnostic laboratories segment held the largest Middle East & Africa molecular diagnostics market share in 2022.

Based on country, the Middle East & Africa molecular diagnostics market has been categorized into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa molecular diagnostics market in 2022.

Abbott Laboratories, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd, Illumina Inc, Novartis AG, Qiagen NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Middle East & Africa molecular diagnostics market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa molecular diagnostics market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa molecular diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the molecular diagnostics market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution